Phase 2a MIB-626 vs. Placebo COVID-19

Summary

The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by longitudinal changes in serum creatinine concentration, and in attenuating the inflammatory response to the infection.

Timeline

Start

2021-10-26

Primary completion

2023-08-17

Completion

2023-08-17

Publications

• Pencina KM, Leaf DE, Valderrabano RJ, Waikar SS, Mehta TS, Shang YV, Latham NK, John T, Volpi E, Fusco D, Memish-Beleva Y, Krishnamurthy S, Lavu S, Karmi S, Livingston DJ, Bhasin S. Oral MIB-626 (beta Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial. FASEB Bioadv. 2025 Jun 18;7(8):e70011. doi: 10.1096/fba.2025-00014. eCollection 2025 Aug.

Drugs

Indications